Monoclonal antibodies targeting chemerin led to reduced lipid storage and diminished renal cancer growth by alleviating the suppression of fatty acid oxidation and ferroptosis induced by chemerin [48]. This evidence concerns the gene RARRES2 and renal carcinoma.